Finasteride Tablet, Film Coated
Product Images NDC 70518-3600

11 FDA label images from Remedyrepack Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 70518-3600). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structutre (Finasteride Structure)

Structutre (Finasteride Structure)
Chemical structure diagram of finasteride showing its characteristic steroid backbone with attached functional groups, including ketone and amide groups, as part of its molecular makeup.*
FDA Label Image

Finasteride-fig.1 (Finasteride Fig.1)

Finasteride-fig.1 (Finasteride Fig.1)
A line graph showing mean change from baseline plus or minus one standard error over a four-year period. It compares two groups: one treated with Finasteride and the other with a placebo. The graph shows the number of subjects in each group at baseline and at each yearly interval up to year four, illustrating a greater downward trend in the Finasteride group compared to placebo.*
FDA Label Image

Finasteride-fig.2 (Finasteride Fig.2)

Finasteride-fig.2 (Finasteride Fig.2)
A line graph displaying the percent of patients over 48 months of observation time comparing Finasteride and placebo groups. The Finasteride group shows a consistently lower percent of patients compared to the placebo group. The graph includes cumulative event counts and number at risk per year for both groups in a table below the chart.*
FDA Label Image

Finasteride-fig.3 (Finasteride Fig.3)

Finasteride-fig.3 (Finasteride Fig.3)
A line graph depicting the mean percent change from baseline over four years for two groups: Placebo and Finasteride. The y-axis shows percent change from baseline, ranging from -20 to 20. The x-axis shows time points: Baseline, Year 1, Year 2, Year 3, and Year 4. The Placebo group (circles) shows an increasing trend, while the Finasteride group (squares) shows a decreasing trend. Sample sizes for each group at each time point are listed below the x-axis.*
FDA Label Image

Finasteride-fig4a (Finasteride Fig4a)

Finasteride-fig4a (Finasteride Fig4a)
A line chart showing mean percent change from baseline over a 4-year period comparing placebo and finasteride groups. The x-axis represents time points from baseline through year 4. The y-axis shows mean percent change with error bars denoting standard error. The finasteride group shows a positive increase, while the placebo group shows a decline over time.*
FDA Label Image

Finasteride-fig.5 (Finasteride Fig.5)

Finasteride-fig.5 (Finasteride Fig.5)
A line graph showing the percentage of participants with an event over 5.5 years from randomization. Four lines represent placebo, finasteride, doxazosin, and combination treatments, illustrating event rates increasing over time, with placebo having the highest event rate and combination the lowest.*
FDA Label Image

Mm1 (Finasteride 5mg 70518 3600 00)

Mm1 (Finasteride 5mg 70518 3600 00)
Label for Finasteride 5 mg film-coated tablet, quantity 1 tablet, repackaged by RemedyRepack Inc. It indicates prescription use only (RX ONLY) and includes warnings against use or handling by women or children. Manufactured by Ascend Labs, LLC in Montvale, NJ. Storage instructions are also provided.*
FDA Label Image

Mm2 (Finasteride 5mg 70518 3600 01)

Mm2 (Finasteride 5mg 70518 3600 01)
Label for Finasteride tablet, film coated, 5 mg strength, with a quantity of 30 tablets per box. The product is labeled as prescription only (RX ONLY) and is repackaged by RemedyRepack Inc. The label includes warnings about use by women and children and instructions to protect from moisture. The NDC number visible is 70518-3600-01.*
FDA Label Image

Mm3 (Finasteride 5mg 70518 3600 02)

Mm3 (Finasteride 5mg 70518 3600 02)
Finasteride 5 mg film-coated tablets packaged in a quantity of 30. Label includes warnings that finasteride should not be used by women or children, and should not be handled if tablets are crushed or broken. Manufactured by Ascend Labs and repackaged by RemedyRepack Inc., with storage instructions and NDC 70518-3600-02. The label features the RemedyRepack logo and dosing information references an insert.*
FDA Label Image

Mm4 (Finasteride 5mg 70518 3600 03)

Mm4 (Finasteride 5mg 70518 3600 03)
Finasteride 5 mg film-coated tablets packaging label showing quantity of 30 tablets. Includes the proprietary name Finasteride, dosage strength 5 mg, and labeler RemedyRepack Inc. NDC number 70518-3600-03 is visible. The label contains usage warnings, storage instructions, and repackaging information by RemedyRepack, with contact details. The lot number and expiration date fields are blank.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Finasteride 5 mg film-coated tablets packaging label from RemedyRepack Inc. The label indicates a quantity of 30 tablets per box. It includes the NDC number 70518-3600-01, manufacturer information (Ascend Labs, LLC), and warnings to keep out of reach of children and not to be used or handled by women or children. Storage directions and repackager contact details are also present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.